Skip to main content
Clinical Trials/NCT04655326
NCT04655326
Completed
Not Applicable

Assessment of Customized Probiotic Therapy for Children and Adults With Autism Spectrum Disorder

Arizona State University1 site in 1 country296 target enrollmentOctober 15, 2020
InterventionsFlore

Overview

Phase
Not Applicable
Intervention
Flore
Conditions
Autism Spectrum Disorder
Sponsor
Arizona State University
Enrollment
296
Locations
1
Primary Endpoint
Parent Global Impressions of Autism
Status
Completed
Last Updated
23 days ago

Overview

Brief Summary

This is a study of the effect of a customized probiotic on children and adults with autism, including effects on autism symptoms and gastrointestinal symptoms.

Detailed Description

SunGenomics provides its customers with a customized probiotic based on an analysis of the microbiota in their stool samples. Customers who have autism spectrum disorders are invited to participate in this study by completing several questionnaires about their medical history, diet, autism symptoms, and gastrointestinal symptoms before taking the probiotic, and to repeat those questionnaires approximately 3 months later. This is effectively an open-label study.

Registry
clinicaltrials.gov
Start Date
October 15, 2020
End Date
July 12, 2025
Last Updated
23 days ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

James B Adams

President's Professor

Arizona State University

Eligibility Criteria

Inclusion Criteria

  • New client of Sun Genomics (has applied for testing and treatment, but not yet begun treatment)
  • Diagnosis of ASD (initially based on self-report of ASD diagnosis by appropriate medical professional, and then verified by an evaluation of the Social Responsiveness Scale (SRS-2) by ASU staff.
  • Children and adults ages 2.5-75 years

Exclusion Criteria

  • Antibiotic use in the last two months (not counting topical antibiotics)
  • Any changes in medications, nutritional supplements, therapies, in the last two months, or any plans to change them during the first 3 months of probiotic treatment.

Arms & Interventions

Treatment Group

Each participant receives a customized probiotic based on the results of the test of their microbiota

Intervention: Flore

Outcomes

Primary Outcomes

Parent Global Impressions of Autism

Time Frame: change in score between baseline and 3 months

questionnaire which assesses 20 different autism-related symptoms on a 7-point scale

Parent Global Impressions of Autism - Change

Time Frame: change in score between baseline and 3 months

The PGIA-Change assesses the change in 20 different autism-related symptoms on a 7-point scale, from -3 (much worse) to 0 (no change) to +3 (much better) Note that this is a different scale than the PGIA-Baseline, which assesses severity on an absolute scale. The rationale for the two scales is that, based on our clinical experience, it appears that parents can give an approximate value for their child's severity (PGIA-Baseline), but that it is more accurate to ask them about change (with the PGIA-Change) than to ask them about severity again and compare it vs a baseline score (PGIA-Baseline).

Secondary Outcomes

  • Social Responsiveness Scale(change in score between baseline and 3 months)
  • Gastrointestinal Symptom Rating Scale(change in score between baseline and 3 months)

Study Sites (1)

Loading locations...

Similar Trials